Skip to content
PeptideHormone

Maridebart cafraglutide vs Survodutide

GLP-1 agonism paired with GIP receptor antagonism — the opposite GIP direction to tirzepatide. A dual glucagon and GLP-1 receptor agonist — the co-agonist that skips GIP and aims at the liver. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.

Maridebart cafraglutide
MariTide
Survodutide
BI 456906
Also known as——
TypeAnalogAnalog
EvidenceInvestigationalInvestigational
FamilyIncretins & metabolicIncretins & metabolic
ClassGLP-1 agonist–GIP-antagonist peptide–antibody conjugateGlucagon/GLP-1 dual receptor agonist (acylated peptide)
Receptor / targetGLP-1 receptor (agonist) + GIP receptor (antagonist)Glucagon receptor (GCGR) + GLP-1 receptor
Molecular weight≈150,000 Da≈4,800 Da
Half-life
~21 days (monthly dosing)
Model dosing
engineered for once-weekly dosing
Based onGlucagon-like peptide-1Glucagon-like peptide-1

Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.

Common questions

What is the difference between Maridebart cafraglutide and Survodutide?
Maridebart cafraglutide is an engineered analog based on Glucagon-like peptide-1; Survodutide is an engineered analog based on Glucagon-like peptide-1. Maridebart cafraglutide signals at GLP-1 receptor (agonist) + GIP receptor (antagonist); Survodutide signals at Glucagon receptor (GCGR) + GLP-1 receptor.
How do the half-lives of MariTide and BI 456906 compare?
The reported circulating half-life of Maridebart cafraglutide is ~21 days (monthly dosing); Survodutide is engineered for once-weekly dosing. These are reference values for the native or representative form — educational only, not dosing advice.

Prefer the other order? Survodutide vs Maridebart cafraglutide. Or open the interactive comparison tool to add more molecules.